Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (71-80 of 596) with videos related to

Pageof 60
Sort By:
Haematologica|September 26, 2024
Unraveling the germline inheritance of the <i>JAK2</i>F556V gene mutation in familial thrombocythemia: a comprehensive analysis of 11 family members and potential implications for surveillanceManja Meggendorfer, Torsten Haferlach, Maria K Beykirch, et al.
Haematologica|April 28, 2018
The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasmsManja Meggendorfer, Sabine Jeromin, Claudia Haferlach, et al.
Leukemia & Lymphoma|April 19, 2019
RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcomeAnna Stengel, Wolfgang Kern, Manja Meggendorfer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Prognosis in therapy-related acute myeloid leukemia and impact of karyotypeWolfgang Kern, Torsten Haferlach, Susanne Schnittger, et al.
Medizinische Klinik (Munich, Germany : 1983)|September 20, 2007
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]Torsten Haferlach, Ulrike Bacher, Wolfgang Kern, et al.
Thescientificworldjournal|February 8, 2011
Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemiaUlrike Bacher, Torsten Haferlach, Boris Fehse, et al.
Genes, Chromosomes & Cancer|May 25, 2016
The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutationsAnna Stengel, Wolfgang Kern, Torsten Haferlach, et al.
Cancer|October 17, 2006
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemiasWolfgang Kern, Alexander Kohlmann, Claudia Schoch, et al.
Leukemia|May 5, 2018
Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm-a comparison of 756 casesConstance Baer, Christian Pohlkamp, Claudia Haferlach, et al.
Blood|May 9, 2007
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemiaFrank Dicker, Claudia Haferlach, Wolfgang Kern, et al.
Pageof 60

Showing results (71-80 of 596) with videos related to

Sort By:
Pageof 60
Haematologica|September 26, 2024
Unraveling the germline inheritance of the <i>JAK2</i>F556V gene mutation in familial thrombocythemia: a comprehensive analysis of 11 family members and potential implications for surveillanceManja Meggendorfer, Torsten Haferlach, Maria K Beykirch, et al.
Haematologica|April 28, 2018
The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasmsManja Meggendorfer, Sabine Jeromin, Claudia Haferlach, et al.
Leukemia & Lymphoma|April 19, 2019
RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcomeAnna Stengel, Wolfgang Kern, Manja Meggendorfer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Prognosis in therapy-related acute myeloid leukemia and impact of karyotypeWolfgang Kern, Torsten Haferlach, Susanne Schnittger, et al.
Medizinische Klinik (Munich, Germany : 1983)|September 20, 2007
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]Torsten Haferlach, Ulrike Bacher, Wolfgang Kern, et al.
Thescientificworldjournal|February 8, 2011
Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemiaUlrike Bacher, Torsten Haferlach, Boris Fehse, et al.
Genes, Chromosomes & Cancer|May 25, 2016
The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutationsAnna Stengel, Wolfgang Kern, Torsten Haferlach, et al.
Cancer|October 17, 2006
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemiasWolfgang Kern, Alexander Kohlmann, Claudia Schoch, et al.
Leukemia|May 5, 2018
Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm-a comparison of 756 casesConstance Baer, Christian Pohlkamp, Claudia Haferlach, et al.
Blood|May 9, 2007
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemiaFrank Dicker, Claudia Haferlach, Wolfgang Kern, et al.
Pageof 60